Form 4 for LNTH Lantheus Holdings, Inc.
Accepted 2024-03-05 00:00:00 ET · period of report 2024-03-01 · accession 0000950170-24-026662 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-03-05 | 2024-03-01 | LNTH | Provost Jean-Claude | Chief Medical Off | A - Grant | $0.00 | +18.6K | 39.4K | +89% | $0 |
| DI | 2024-03-05 | 2024-03-01 | LNTH | Provost Jean-Claude | Chief Medical Off | A - Grant | $0.00 | +11.0K | 11.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-01 | A | A | 18,564 | $0.00 | 39,387 | I By Theranostics Consulting SAS | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2024-03-01 | A | A | 10,998 | $0.00 | 10,998 | I By Theranostics Consulting SAS | $64.64 · — to 2034-03-01 | 10,998 Common Stock | (F2) The option vests in three equal annual installments beginning on March 1, 2025. |